18F-FDG PET/CT Evaluation of Crizotinib and Lorlatinib Therapy in Metastatic ROS-1-Positive Non-Small Cell Lung Cancer

Sébastien Dejust , Abdenasser Moubtakir , A. Prevost , K. El Farsaoui , David Morland (1)

1 CRESTIC - Centre de Recherche en Sciences et Technologies de l'Information et de la Communication - EA 3804

ROS-1-positive non-small cell lung cancers (NSCLCs) are rare (approximately 1% of all NSCLCs) and require a first-line treatment by crizotinib. Crizotinib resistance is frequent within the first 12 months of treatment. Lorlatinib is a novel tyrosine kinase inhibitor of ROS-1 recently indicated for metastatic or locally advanced crizotinib-resistant NSCLC. We report the use of lorlatinib as second-line with a complete tumoral response after only 3 months of treatment. This case shows the major role of F-FDG PET/CT in treatment evaluation and monitoring targeted therapy in metastatic NSCLC.

Domaines: Médecine nucléaire

Sébastien Dejust, Abdenasser Moubtakir, A. Prevost, K. El Farsaoui, David Morland. 18F-FDG PET/CT Evaluation of Crizotinib and Lorlatinib Therapy in Metastatic ROS-1-Positive Non-Small Cell Lung Cancer. Clinical Nuclear Medicine, 2020, 45 (3), pp.209-210. ⟨10.1097/RLU.0000000000002912⟩. ⟨hal-02483424⟩